Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Atossa Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Atossa Therapeutics, Inc.’s stock price such as:

• Atossa Therapeutics, Inc.’s current stock price and volume
• Why Atossa Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ATOS from analysts
• ATOS’s stock price momentum as measured by its relative strength

About Atossa Therapeutics, Inc. (ATOS)

Before we jump into Atossa Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Want to learn more about Atossa Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Atossa Therapeutics, Inc..

Atossa Therapeutics, Inc.’s Stock Price as of Market Close

As of December 05, 2025, 4:00 PM, CST, Atossa Therapeutics, Inc.’s stock price was $0.799.

Atossa Therapeutics, Inc. is up 5.24% from its previous closing price of $0.760.

During the last market session, Atossa Therapeutics, Inc.’s stock traded between $0.767 and $0.810. Currently, there are approximately 129.17 million shares outstanding for Atossa Therapeutics, Inc..

Atossa Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Atossa Therapeutics, Inc. Stock Price History

Atossa Therapeutics, Inc.’s (ATOS) price is currently up 2.8% so far this month.

During the month of December, Atossa Therapeutics, Inc.’s stock price has reached a high of $0.810 and a low of $0.685.

Over the last year, Atossa Therapeutics, Inc. has hit prices as high as $1.298 and as low as $0.553. Year to date, Atossa Therapeutics, Inc.’s stock is down 15.34%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Atossa Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 05, 2025, there were 0 analysts who downgraded Atossa Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Atossa Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Atossa Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Atossa Therapeutics, Inc. (ATOS) by visiting AAII Stock Evaluator.

Relative Price Strength of Atossa Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 05, 2025, Atossa Therapeutics, Inc. has a weighted four-quarter relative price strength of -9.35%, which translates to a Momentum Score of 26 and is considered to be Weak.

Want to learn more about how Atossa Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Atossa Therapeutics, Inc. Stock Price: Bottom Line

As of December 5, 2025, Atossa Therapeutics, Inc.’s stock price is $0.799, which is up 5.24% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Atossa Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.